Summary

• Johnson & Johnson cannot recommend any practices, procedures, handling or dosage and administration techniques that deviate from the approved product labeling.
• AKEEGA is not commercially available as a solution or suspension.
• Data from clinical studies including pharmacokinetic (PK) and pharmacodynamic (PD) studies of crushing, splitting, or dispersion of AKEEGA tablets for administration have not been published.
• A descriptive, observational, transverse study evaluated survey results from 950 patients regarding splitting or crushing medications. The purpose of the survey was to evaluate patient knowledge of oral medications that could or could not be crushed or split and to create a list of medications available in Mexico that should not be crushed or split. Mucosal irritation was noted as rationale for including abiraterone acetate in a list of medications that should not be split or crushed.¹

CLINICAL DATA

No relevant clinical study information was identified for crushing, splitting, or dispersion of AKEEGA tablets.

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DerwentDrug File (and/or other resources, including internal/external databases) conducted on 23 May 2024 did not identify any relevant citations pertaining to this topic in patients with prostate cancer.